Display options
Cite
Ma Y, Wu X, Yu J, et al. Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? a systematic review and network meta-analysis. Oncotarget. 2017;8(51):89108-89118doi: 10.18632/oncotarget.19059.
Ma, Y., Wu, X., Yu, J., Zhu, J., Pen, X., & Meng, X. (2017). Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? a systematic review and network meta-analysis. Oncotarget, 8(51), 89108-89118. https://doi.org/10.18632/oncotarget.19059
Ma, Yan, et al. "Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? a systematic review and network meta-analysis." Oncotarget vol. 8,51 (2017): 89108-89118. doi: https://doi.org/10.18632/oncotarget.19059
Ma Y, Wu X, Yu J, Zhu J, Pen X, Meng X. Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? a systematic review and network meta-analysis. Oncotarget. 2017 Jul 06;8(51):89108-89118. doi: 10.18632/oncotarget.19059. eCollection 2017 Oct 24. PMID: 29179503; PMCID: PMC5687673.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 06;8(51):89108-89118. doi: 10.18632/oncotarget.19059. eCollection 2017 Oct 24.

Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? a systematic review and network meta-analysis.

Oncotarget

Yan Ma, Xiaofen Wu, Jingwen Yu, Jinyan Zhu, Xia Pen, Xianjun Meng

Affiliations

  1. Center of Experiment Teaching, Shenyang Normal University, Shenyang 110034, P.R. China.
  2. The Sixth People's Hospital of Shenyang, Shenyang 110005, P.R. China.
  3. Food Inspection Monitoring Center of Zhuanghe, Dalian 116400, P.R. China.
  4. College of Food Science, Shenyang Agriculture University, Shenyang 110866, P.R. China.

PMID: 29179503 PMCID: PMC5687673 DOI: 10.18632/oncotarget.19059

Abstract

OBJECTIVE: To assess the comparative efficacy and safety of polysaccharide K (PSK), with or without chemotherapy, for patients with gastrointestinal cancer (GIC) through a systematic review and network meta-analysis.

MATERIALS AND METHODS: We performed a network meta-analysis to identify evidence from randomized controlled trials. We searched PubMed, Embase and the Cochrane Library for publications up to May 2017. The prespecified primary efficacy outcomes were 1-7 year overall survival (OS), while the secondary efficacy outcomes were 1-7 year disease-free survival (DFS); we performed subgroup analyses and meta-regressions according to the cancer type (colorectal, esophagus and gastric cancer) and treatment arms (with or without chemotherapy). Safety outcomes were side effects of PSK. We conducted pairwise meta-analyses using a random-effects model and then performed random-effects network meta-analyses.

RESULTS: A total of 23 trials were eligible, involving 10684 patients and 13 intervention arms. PSK treatment significantly increased 1-5 year OS and resulted in positive trends in 6-7 year OS; significant increases were also found in 1-7 year DFS, while no increase in side effects was observed. Significant efficacy outcomes obvious in colorectal and gastric cancer groups, as well as PSK combined with chemotherapy groups (iv, po, iv+po). Network meta-analysis revealed that PSK combined with chemotherapy was superior, with significantly increased 3-year and 5-year OS. The study is registered with PROSPERO (CRD42017065193).

CONCLUSIONS: The adjuvant immunochemotherapy agent PSK is effective and safe for patients with GIC. PSK combined with chemotherapy appears to be the preferred application of PSK.

Keywords: PSK; gastrointestinal cancer; immunochemotherapy; network meta-analysis; polysaccharide K

Conflict of interest statement

CONFLICTS OF INTEREST The authors have declared that there is no competing interest.

References

  1. Surg Today. 2012 Jan;42(1):8-28 - PubMed
  2. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
  3. Anticancer Res. 2010 Mar;30(3):993-9 - PubMed
  4. J Surg Oncol. 1990 Nov;45(3):169-72 - PubMed
  5. Oncotarget. 2017 Jul 18;8(29):48410-48423 - PubMed
  6. Phys Ther. 2003 Aug;83(8):713-21 - PubMed
  7. BMJ. 2008 Apr 26;336(7650):924-6 - PubMed
  8. Cancer Treat Rev. 1984 Jun;11(2):131-55 - PubMed
  9. CA Cancer J Clin. 2012 Sep-Oct;62(5):283-98 - PubMed
  10. J Clin Epidemiol. 2011 Feb;64(2):163-71 - PubMed
  11. BMC Cancer. 2008 Mar 24;8:78 - PubMed
  12. Jpn J Surg. 1990 Mar;20(2):127-36 - PubMed
  13. Dis Colon Rectum. 2007 Aug;50(8):1169-81 - PubMed
  14. Dis Colon Rectum. 1992 Feb;35(2):123-30 - PubMed
  15. PLoS One. 2013 Oct 03;8(10):e76654 - PubMed
  16. Ann Intern Med. 2015 Jun 2;162(11):777-84 - PubMed
  17. Int J Colorectal Dis. 2004 Mar;19(2):157-64 - PubMed
  18. Int J Immunopharmacol. 1993 Aug;15(6):745-50 - PubMed
  19. Dis Colon Rectum. 2003 Aug;46(8):1060-8 - PubMed
  20. Biotherapy. 1992;4(2):117-28 - PubMed
  21. BMJ. 2009 Jul 21;339:b2535 - PubMed
  22. Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1431-7 - PubMed
  23. Anticancer Res. 2005 Mar-Apr;25(2B):1377-84 - PubMed
  24. Immunol Lett. 2004 Feb 15;91(2-3):229-38 - PubMed
  25. Oncology. 2008;74(3-4):143-9 - PubMed
  26. Lancet Oncol. 2007 Mar;8(3):226-34 - PubMed
  27. Oncol Rep. 2000 Sep-Oct;7(5):1157-61 - PubMed
  28. Onkologie. 2013;36(7-8):421-6 - PubMed
  29. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  30. Br J Cancer. 2004 Mar 8;90(5):1003-10 - PubMed
  31. Anticancer Res. 2004 Mar-Apr;24(2B):639-47 - PubMed
  32. Cancer Invest. 1995;13(4):363-9 - PubMed
  33. Surg Today. 1999;29(6):504-10 - PubMed
  34. Jpn J Surg. 1988 Nov;18(6):681-6 - PubMed
  35. Ann Intern Med. 2007 Apr 17;146(8):580-90 - PubMed
  36. Am J Clin Oncol. 1995 Jun;18(3):216-22 - PubMed
  37. Cancer Immunol Immunother. 1990;31(5):261-8 - PubMed
  38. Int J Clin Oncol. 2010 Apr;15(2):145-52 - PubMed
  39. Oncotarget. 2017 May 23;8(21):34727-34735 - PubMed
  40. Med Decis Making. 2013 Jul;33(5):641-56 - PubMed
  41. Lymphokine Res. 1990 Winter;9(4):475-83 - PubMed
  42. Stat Methods Med Res. 2008 Jun;17(3):279-301 - PubMed
  43. J Clin Epidemiol. 2011 Apr;64(4):401-6 - PubMed
  44. Oncol Rep. 2006 Apr;15(4):861-8 - PubMed
  45. Biotherapy. 1991;3(4):287-95 - PubMed
  46. BMJ. 2013 May 14;346:f2914 - PubMed
  47. Lancet. 2007 Dec 15;370(9604):2020-9 - PubMed
  48. Lancet. 1994 May 7;343 (8906):1122-6 - PubMed
  49. Surg Today. 1992;22(6):530-6 - PubMed
  50. Gan. 1976 Oct;67(5):713-6 - PubMed
  51. Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):275-81 - PubMed

Publication Types